Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 11/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 6/20 | 0.39 |
| ▸ | RAF1 | P04049 | 5/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958278 | 1.00 | KLKB1 (0.40) | KLKB1ACVRL1BRAFRAF1METTL3 | |
| SCHEMBL24737728 | 0.86 | ACVRL1 (0.48) | KLKB1ACVRL1BRAFMETTL3JAK2 | |
| SCHEMBL29879447 | 0.82 | KLKB1 (0.38) | KLKB1METTL3 | |
| SCHEMBL29302927 | 0.82 | KLKB1 (0.38) | KLKB1METTL3 | |
| SCHEMBL27033947 | 0.81 | PIK3C3 (0.39) | KLKB1ACVRL1BRAFMETTL3TYK2 | |
| SCHEMBL27033738 | 0.80 | KLKB1 (0.43) | KLKB1BRAFMETTL3 | |
| SCHEMBL29879527 | 0.80 | KLKB1 (0.41) | KLKB1ACVRL1METTL3TYK2 | |
| SCHEMBL29137049 | 0.80 | KLKB1 (0.41) | KLKB1ACVRL1METTL3TYK2 | |
| SCHEMBL29879879 | 0.80 | KLKB1 (0.41) | KLKB1ACVRL1METTL3TYK2 | |
| SCHEMBL24737729 | 0.80 | KLKB1 (0.41) | KLKB1ACVRL1METTL3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885ACVRL1 3030/4885BRAF 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.